文献速递脑血管病外科神经肿瘤功能神经外科

斯坦福20年7000例立体定向放射外科经验:超越手术刀的探索

The Stanford stereotactic radiosurgery experience on 7000 patients over 2 decades (1999-2018): looking far beyond the scalpel.
PubMed 文献 · J Neurosurg · 2021-04-02

该研究回顾斯坦福1999-2018年7000余例接受射波刀治疗的颅内与脊柱病变患者,并综述1990-2019年文献。结果显示射波刀使用呈正线性趋势(r²=0.80),在颅内和脊柱动静脉畸形、脑与脊柱转移瘤、良性肿瘤及三叉神经痛中应用增长显著。

要点

  • 射波刀治疗颅内和脊柱病变的使用量20年间呈持续上升趋势。
  • 颅内和脊柱动静脉畸形治疗方式向射波刀转变具有统计学显著性(p<0.05)。
  • 脑与脊柱转移瘤、脑膜瘤、胶质母细胞瘤的治疗趋势偏向射波刀但未达统计学显著。

核心结论

  • 证据表明射波刀广泛用于治疗多种神经系统疾病,且使用量呈线性增长。

研究设计与样本

  • 同时检索1990年1月至2019年6月在线文献数据库进行文献综述。
  • 采用决定系数(r²)评估射波刀使用随时间的变化,t检验评估治疗模式变化,显著性水平α=0.05。

主要发现

  • 7000余例患者中射波刀使用呈正线性趋势(r²=0.80)。
  • 颅内和脊柱动静脉畸形的r²分别为0.89和0.95,脑和脊柱转移瘤的r²分别为0.97和0.79。
  • 脑膜瘤、前庭神经鞘瘤和颈静脉球瘤的r²分别为0.85、0.76和0.89。
  • 胶质母细胞瘤和三叉神经痛的r²分别为0.54和0.81。
  • 颅内和脊柱动静脉畸形的治疗模式向射波刀转变具有统计学显著差异(p<0.05);脑与脊柱转移瘤、脑膜瘤和胶质母细胞瘤的治疗趋势偏向射波刀但无统计学显著性。

临床怎么用

  • 射波刀可作为颅内和脊柱动静脉畸形、转移瘤、良性肿瘤及三叉神经痛等疾病的一种无框架非侵入性治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The CyberKnife (CK) has emerged as an effective frameless and noninvasive method for treating a myriad of neurosurgical conditions. Here, the authors conducted an extensive retrospective analysis and review of the literature to elucidate the trend for CK use in the management paradigm for common neurosurgical diseases at their institution. METHODS: A literature review (January 1990-June 2019) and clinical review (January 1999-December 2018) were performed using, respectively, online research databases and the Stanford Research Repository of patients with intracranial and spinal lesions treated with CK at Stanford. For each disease considered, the coefficient of determination (r2) was estimated as a measure of CK utilization over time. A change in treatment modality was assessed using a t-test, with statistical significance assessed at the 0.05 alpha level. RESULTS: In over 7000 patients treated with CK for various brain and spinal lesions over the past 20 years, a positive linear trend (r2 = 0.80) in the system's use was observed. CK gained prominence in the management of intracranial and spinal arteriovenous malformations (AVMs; r2 = 0.89 and 0.95, respectively); brain and spine metastases (r2 = 0.97 and 0.79, respectively); benign tumors such as meningioma (r2 = 0.85), vestibular schwannoma (r2 = 0.76), and glomus jugulare tumor (r2 = 0.89); glioblastoma (r2 = 0.54); and trigeminal neuralgia (r2 = 0.81). A statistically significant difference in the change in treatment modality to CK was observed in the management of intracranial and spinal AVMs (p < 0.05), and while the treatment of brain and spine metastases, meningioma, and glioblastoma trended toward the use of CK, the change in treatment modality for these lesions was not statistically significant. CONCLUSIONS: Evidence suggests the robust use of CK for treating a wide range of neurological conditions.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Fatima N, Meola A, Ding VY, et al. The Stanford stereotactic radiosurgery experience on 7000 patients over 2 decades (1999-2018): looking far beyond the scalpel. J Neurosurg. 2021. PMID: 33799297. doi:10.3171/2020.9.JNS201484

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。